Participants
Participants of this study represented a selection of individuals from two large multi-center studies: the Swedish BioFinder Study (BioF; http://biofinder.se/) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI; http://adni.loni.usc.edu). Both studies were designed to accelerate the discovery of biomarkers indicating progression of Alzheimer’s disease pathology. Participants were selected based on the following inclusion criteria: participants must (i) have a Flortaucipir-PET scan, (ii) have either a β-amyloid-PET scan (for ADNI: [18F]-Florbetapir, for BioF: [18F]-Flutemetamol) or lumbar puncture measuring CSF Aβ1–42. In addition, participants were required to be cognitively unimpaired, have a clinical diagnosis of mild cognitive impairment, or have a clinical diagnosis of Alzheimer’s dementia with biomarker evidence of β-amyloid (Aβ) positivity. For…
